A Pooled Analysis of the Efficacy and Safety of Saxagliptin as Monotherapy in Patients with Type 2 Diabetes
| Autor: | John Xu, Brian S Bryzinski, Boaz Hirshberg, Nayyar Iqbal |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
endocrine system diseases business.industry nutritional and metabolic diseases Type 2 diabetes Pharmacology Hypoglycemia Saxagliptin medicine.disease Placebo Metformin Clinical trial chemistry.chemical_compound chemistry Internal medicine medicine Glycated hemoglobin business Adverse effect medicine.drug |
| Zdroj: | Journal of Diabetes and Metabolism. |
| ISSN: | 2155-6156 |
| DOI: | 10.4172/2155-6156.1000524 |
| Popis: | Objective: Saxagliptin is a once-daily, orally administered dipeptidyl peptidase-4 inhibitor, approved for the treatment of type 2 diabetes mellitus (T2DM). In 4 double-blind, placebo-controlled, phase 3 trials, saxagliptin 2.5 or 5 mg significantly reduced glycated hemoglobin (HbA1c) from baseline at 24 weeks. A pooled analysis of these clinical trials was conducted to assess the therapeutic profile of saxagliptin monotherapy. Methods: A post hoc pooled analysis of 4 saxagliptin monotherapy trials in patients with T2DM was conducted to determine the consistency of treatment effects, assessed as change from baseline in HbA1c at week 24, in patient subgroups stratified by race, sex, age, and baseline HbA1c. Secondary end points included change from baseline at week 24 in fasting plasma glucose and proportion of patients achieving HbA1c |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|